tanci
year
time
period
today
global
mortal
prevent
rate
million
live
save
worldwid
year
immun
program
world
health
organ
immun
program
includ
origin
six
childhood
vaccinesagainst
diphtheria
tetanu
pertussi
whoop
cough
measl
polio
tuberculosisplu
recent
introduc
vaccin
hepat
b
viru
haemophilu
influenza
type
b
mump
pneumococc
diseas
rotaviru
rubella
german
measl
region
nation
local
highrisk
occup
immun
program
ad
vaccin
varicella
chickenpox
meningococc
typhoid
fever
herp
zoster
shingl
human
papillomaviru
yellow
fever
japanes
enceph
well
list
investig
statu
biodefens
vaccin
due
larg
part
worldwid
vaccin
program
global
annual
rate
underfiveyearold
death
reduc
half
million
million
nevertheless
report
also
reveal
low
incom
famili
repres
time
averag
case
rate
immun
coverag
incomplet
mani
region
vaccin
stock
shortag
report
case
rate
recent
increas
target
diseas
beyond
remark
impact
mortal
rate
vaccin
also
help
rais
life
qualiti
work
product
social
equiti
avert
untold
number
disabl
postinfect
diseas
sequela
notabl
blind
deaf
neurolog
disord
cite
list
accomplishmentsth
global
erad
smallpox
activ
endgam
strateg
plan
erad
polio
region
initi
elimin
control
sever
remain
vaccineprevent
childhood
diseas
plu
robust
intern
postmarket
surveil
program
period
benefittocost
assess
valu
prophylact
vaccin
infecti
diseas
remain
undisput
scientif
medic
public
polici
commun
well
gener
public
larg
howev
signific
advanc
knowledg
technolog
help
rapidli
expand
product
develop
goal
immun
beyond
tradit
proven
capabl
vaccinolog
challeng
new
target
includ
vaccin
recent
ancient
pathogen
human
immunodefici
viru
hiv
pandem
influenza
malaria
improv
capabl
extend
immun
young
elderli
immun
compromis
popul
postexposur
prophylaxi
indic
prepared
biolog
threat
agent
anthrax
ebola
viru
emerg
pandem
strain
influenza
middl
east
respiratori
syndrom
coronaviru
methicillinresist
staphylococcu
aureu
well
immun
treatment
protect
import
noninfecti
target
includ
cancer
autoimmun
diseas
neurolog
disord
medic
condit
adjuv
broader
phenomenon
adjuvant
partner
vaccin
success
throughout
histori
proport
vaccin
formul
ad
adjuv
increas
time
compris
half
vaccin
either
licens
clinic
test
fig
detail
understand
adjuv
recent
appear
discoveri
deepen
character
immun
signal
biomolecul
physicochem
structur
deriv
pathogen
relat
cell
damag
refer
pathogen
associ
molecular
pattern
pamp
damag
associ
molecular
pattern
damp
growth
understand
recent
includ
contribut
structur
vaccinolog
synthet
biolog
initi
ad
vaccin
empir
discoveri
adjuv
present
develop
deduct
ration
design
test
inform
incorpor
adjuv
materi
continu
essenti
compon
forthcom
vaccin
particularli
vaccin
engin
meet
rise
global
demand
greater
potenc
use
less
antigen
wider
diseas
popul
coverag
fewer
formul
easier
administr
reduc
logist
cost
first
look
back
origin
adjuv
focu
classic
recent
adjuv
exampl
categori
ionic
polym
ionic
materi
recent
advanc
immunolog
materi
scienc
improv
understand
capabl
aluminum
salt
remain
wide
use
adjuv
synthet
polym
repres
newer
materi
show
wide
abil
promis
adjuv
technolog
emerg
medic
necess
regulatori
pressur
scientif
discoveri
recount
semin
event
lead
develop
use
adjuv
medic
tool
continu
evolv
capabl
import
rapidli
ever
histori
show
empir
observ
test
critic
discoveri
develop
first
immunolog
adjuv
recognit
need
supplement
process
formul
improv
immun
aros
expans
vaccin
design
beyond
attenu
inactiv
kill
strain
prepar
use
sinc
dawn
vaccinolog
earli
centuri
difficulti
accompani
initi
toxoid
type
vaccin
compris
dilut
activ
toxin
administ
antitoxin
hors
antiserum
discov
forti
year
earlier
kitasato
von
behr
von
behr
later
first
nobel
prize
medicin
toxinserum
type
vaccin
market
boldli
desir
protect
afford
diphtheria
tetanu
commonli
fatal
childhood
diseas
unlik
endem
epidem
diseas
await
effect
vaccin
bacteri
exotoxin
protein
associ
diseas
reproduc
diseas
patholog
isol
apart
etiolog
live
infecti
organ
activ
exotoxin
could
induc
neutral
antibodi
demonstr
first
anim
test
later
passiv
transfer
human
small
dose
could
induc
immun
coadministr
protect
antiserum
diphtheria
lead
caus
ill
death
among
children
estim
case
death
annual
variou
toxinantitoxin
product
afford
prophylaxi
howev
tetanuscontamin
diphtheria
antiserum
caus
death
children
st
loui
soon
afterward
children
die
new
jersey
tetanu
contamin
smallpox
vaccin
tragedi
underscor
need
regul
standard
qualiti
control
drove
legisl
action
public
safeti
biolog
control
act
launch
feder
requir
annual
licens
inspect
biolog
manufactur
rule
product
test
puriti
standard
qualiti
control
truth
label
also
creat
hygien
laboratori
us
public
health
servic
eventu
becam
nation
institut
health
subsequ
act
amend
ad
consolid
regul
eventu
transfer
oversight
biolog
food
drug
administr
fda
thu
event
groundbreak
first
endur
scheme
nation
regul
pharmaceut
first
premarket
approv
statut
histori
set
preced
shift
retrospect
postmarket
prospect
premarket
govern
review
gener
period
area
research
also
yield
first
biolog
standard
establish
paul
ehrlich
work
von
behr
antiserum
control
variat
content
temperatur
propos
univers
unit
activ
genesi
immunolog
adjuv
emerg
within
set
medic
regulatori
pressur
surround
toxoid
vaccin
antisera
though
detail
knowledg
underli
scienc
adjuv
enhanc
immun
would
coalesc
seri
discoveri
focus
reduc
toxic
diphtheria
toxin
improv
immun
antigen
illustr
incept
adjuv
scienc
methodolog
inactiv
toxin
toxoid
immunogen
protect
toxin
bread
crumb
tapioca
starch
agar
oil
compound
increas
antiserum
titer
slow
releas
elimin
toxoid
fraction
purif
toxoid
precipit
aluminum
salt
provid
robust
immun
protect
guinea
pig
last
achiev
list
effect
preform
aluminum
salt
compar
coprecipit
antigen
aluminum
phosphat
alum
potassium
aluminum
sulfat
connect
line
develop
modern
aluminum
gel
mostli
employ
today
often
consid
togeth
research
shown
variou
aluminum
salt
gel
exhibit
univers
equival
attribut
adjuv
materi
full
chemic
formula
process
formul
aluminum
salt
adjuv
licens
vaccin
public
releas
discoveri
evolut
aluminum
salt
adjuv
survey
one
thread
sever
adjuv
deep
histori
vaccin
develop
illustr
empir
find
foundat
gener
specif
largest
class
adjuv
still
use
today
depict
develop
sever
licens
vaccin
adjuv
shown
fig
illustr
includ
timelin
common
vaccin
class
attenu
kill
serum
toxoid
conjug
etc
technolog
support
new
develop
vaccin
adjuv
reprint
rappuoli
et
al
adjuv
class
use
current
licens
vaccin
includ
emuls
system
liposom
tolllik
receptor
tlr
base
compound
aluminum
salt
discoveri
critic
gener
develop
adjuv
scienc
technolog
introduct
modern
version
adjuv
also
note
adjuv
timelin
fig
current
licens
emuls
system
liposom
type
adjuv
formul
use
vaccin
season
flu
pandem
influenza
hepat
trace
back
freund
complet
adjuv
complet
freund
adjuv
cfa
emuls
system
solubl
antigen
mix
miner
oil
waterinoil
wo
surfact
inactiv
dri
mycobacteria
though
cfa
becam
popular
potenc
deem
toxic
human
use
evidenc
sever
inflammatori
effect
granulomat
reaction
revers
emuls
formul
contain
oilinwat
ow
mixtur
without
mycobacterium
includ
incomplet
freund
adjuv
ifa
less
viscou
easier
prepar
inject
well
less
reactogen
squalen
biodegrad
oil
still
extract
shark
liver
emerg
part
effect
ow
emuls
adjuv
use
licens
vaccin
formul
today
includ
squalen
sorbitan
trioleat
squalen
ph
erol
well
candid
pandem
flu
vaccin
yet
licens
sever
candid
emuls
liposom
adjuv
also
evalu
preclin
clinic
test
yet
licens
includ
glaxosmithklin
adjuv
system
formul
liposom
lipid
mpl
saponin
ow
mpl
saponin
tlr
pattern
recognit
receptor
prr
mechan
action
indic
squalen
emuls
liposom
type
adjuv
though
investig
vehicl
combin
known
tlr
ligand
synthet
compound
mpl
tlr
class
adjuv
present
use
us
licens
vaccin
detoxifi
version
gramneg
bacteri
endotoxin
lipopolysaccharid
lp
signal
innat
immun
via
complex
lp
first
tlr
ligand
mani
pamp
intens
investig
develop
po
tential
adjuv
new
capabl
improv
vaccin
discoveri
bacteri
endotoxin
late
richard
pfieffer
subsequ
demonstr
heat
stabl
substanc
could
evok
neutral
antibodi
suppress
poison
effect
initi
long
line
research
underli
current
knowledg
pamp
tlrdirect
innat
immun
respons
among
sever
discoveri
also
spur
advanc
immunolog
adjuv
medic
report
coley
toxin
extract
infecti
bacteria
success
treat
cancer
almost
year
wide
studi
immunestimul
bacteri
compon
converg
discoveri
understand
certain
microbi
substructur
embodi
pamp
serv
ligand
immun
cell
prr
aka
prr
signal
innat
immun
system
identif
tlr
human
nodlik
receptor
nlr
class
prr
revolution
scienc
practic
vaccin
adjuv
character
develop
evid
synopsi
earli
period
vaccin
develop
determin
scienc
adjuvant
standard
biolog
regul
sinc
varieti
vaccin
type
expand
adjuv
codevelop
vaccin
type
licens
investig
today
except
princip
whole
organ
vaccin
carbohydr
vaccin
larg
bodi
cumul
knowledg
natur
adjuv
develop
test
chang
one
empir
trialanderror
test
toward
one
akin
ration
design
though
much
left
understood
adjuv
mechan
action
particularli
damptyp
class
substanc
sever
field
scienc
intersect
driver
coevolut
vaccin
adjuv
improv
immun
capabl
largest
singl
driver
innov
improv
adjuv
technolog
scientif
knowledg
inform
rapid
growth
primari
data
improv
access
mean
connect
crossreferenc
inform
due
high
interdepend
rapid
pace
develop
share
endeavor
benefit
comprehens
descript
report
network
data
result
test
design
perform
standard
annot
commun
univers
scientif
mean
adjuv
improv
vaccin
effect
modul
immunogen
antigen
deliv
vaccin
product
addit
origin
goal
increas
antibodi
titer
immunolog
adjuv
engin
alter
natur
adapt
immun
respons
antigen
increas
potenc
durat
shorten
time
immun
alter
immun
polar
increas
scope
breadth
diseas
target
patient
popul
tabl
goal
sought
also
align
effort
improv
vaccin
toler
safeti
product
manufactur
stabil
well
aid
cost
global
logist
transport
distribut
stockpil
administr
new
vaccin
includ
underdevelop
challeng
environ
type
vaccin
requir
adjuv
though
total
product
number
licens
indic
exce
vaccin
contain
adjuv
fig
includ
live
attenu
vaccin
adenoviru
bacillu
calmetteguerin
bcg
flu
mump
rubella
vaccin
oral
polio
viru
polio
rotaviru
smallpox
salmonella
typhi
varicella
yellow
fever
split
virion
vaccin
flu
inactiv
vaccin
rabi
inactiv
polioviru
viru
ipv
polio
carbohydr
vaccin
pneumococc
meningococc
typhium
vi
live
attenu
inactiv
split
virion
vaccin
requir
adjuv
includ
suffici
pamp
selfadjuvant
carbohydr
vaccin
requir
adjuv
tcell
independ
carbohydr
antigen
capsular
polysaccharid
directli
bind
bcell
elicit
activ
prolifer
without
mhcrestrict
tcell
help
tabl
immunolog
role
adjuv
vaccin
develop
spons
gener
short
durat
affin
matur
fail
elicit
immunolog
memori
reason
newer
carbohydratebas
vaccin
consist
carbohydr
conjug
protein
provid
tcell
epitop
tcell
depend
respons
capabl
antibodi
class
switch
affin
matur
immunolog
memori
longer
durat
although
adjuv
often
ad
conjug
vaccin
enhanc
tcell
depend
respons
candid
conjug
protein
also
appear
capac
function
simultan
true
adjuv
tlr
interact
exampl
neisseri
porin
signal
via
complex
addit
protein
may
provid
tlrbase
adjuv
effect
fuse
target
protein
antigen
exampl
salmonella
flagellin
interact
genet
fuse
influenza
hemagglutinin
adjuv
promot
immun
stimul
effect
activ
grow
area
research
ongo
discoveri
help
build
area
understand
vaccin
adjuv
immunolog
briefli
discuss
next
today
inform
mechan
immun
potenti
accumul
quit
rapidli
mechan
frequent
challeng
support
experiment
evid
consensu
exit
sever
pathway
involv
adjuv
mechan
action
detail
prr
trl
class
signal
receptor
help
revolution
understand
immun
phenomenolog
summari
locat
plasma
membran
immun
cell
macrophag
dendrit
cell
dc
neutrophil
etc
recogn
pamp
surfac
bacteri
fungal
pathogen
lp
flagellin
endosom
locat
recogn
viral
microbi
rna
dna
sever
prr
describ
nlr
like
helicas
extracellular
ctype
lectin
receptor
function
via
adaptor
protein
tirap
trif
asc
etc
coordin
signal
among
pamp
pathway
prr
includ
tlr
eg
also
recogn
endogen
damp
ligand
like
heat
shock
protein
fibrinogen
fibronectin
produc
cell
damag
injuri
stress
metabol
imbal
activ
tlr
neutrophil
activ
nadph
oxidas
produc
reactiv
oxygen
speci
ro
mediat
releas
damp
drive
inflammatori
respons
way
tlr
nlr
prr
transmit
help
coordin
immunomodulatori
respons
signal
pathogen
endogen
stressor
net
immedi
effect
respons
involv
inflammasom
activ
inflammatori
process
promot
process
secret
proinflammatori
cytokin
interleukin
il
initi
process
drive
recruit
activ
matur
immun
cell
direct
innat
adapt
immun
function
process
heart
function
mechan
immunolog
adjuv
excel
review
publish
great
detail
mechan
tlrdepend
tlrindepend
adjuv
mani
review
provid
gener
summari
illustr
instruct
develop
challeng
refin
model
toward
understand
immun
regul
adjuv
function
natur
concept
model
occasion
requir
adjust
adapt
knowledg
evolv
current
evid
yet
connect
function
aluminum
salt
gel
polyelectrolyt
adjuv
topic
review
known
tlr
pathway
howev
activ
tlrindepend
adjuv
materi
aluminum
oil
emuls
link
damp
pathway
includ
activ
inflammasom
ro
deform
restructur
plasma
membran
play
import
role
though
also
shown
univers
essenti
dampsign
adjuv
interestingli
complex
also
act
extracellular
damp
particl
dispers
neighbor
macrophag
amplifi
inflammatori
respons
gener
role
cell
pathway
depict
fig
reproduc
modifi
slightli
de
gregorio
et
al
illustr
show
tlr
nontlr
adjuv
activ
focu
dc
central
control
adapt
immun
mani
year
particul
colloid
adjuv
aluminum
salt
polym
consid
function
mainli
inert
deliveri
vehicl
assist
antigen
stabil
uptak
deliveri
origin
depot
model
slowreleas
antigen
aluminum
adjuv
challeng
experiment
evid
antigen
desorb
aluminum
adjuv
soon
inject
nevertheless
carrier
transport
role
debunk
antigen
stabil
structur
potenc
greatli
enhanc
bound
aluminum
salt
gel
compar
free
solubl
form
importantli
recent
work
demon
hydrogel
aluminum
oxyhydroxid
salin
formul
result
hydrat
antigen
reestablish
solublelik
structur
compar
formul
plain
alhydrogel
also
contrast
conclus
whether
aluminum
salt
adjuv
intern
antigen
present
cell
recent
report
provid
convinc
evid
intern
particular
fluoresc
molecular
probe
aluminum
lumogallion
use
confirm
intracellular
locat
aluminum
oxyhydroxid
adjuv
taken
mono
cytic
helper
cell
line
thu
immun
activ
support
without
intern
aluminum
adjuv
particl
began
hand
materi
boost
antigen
titer
year
ago
becom
short
list
licens
vaccin
adjuv
long
list
potenti
adjuv
materi
preclin
clinic
test
adjuv
commonli
divid
two
broad
function
categori
deliveri
vehicl
immunopoteni
though
mani
show
function
includ
miner
salt
polyelectrolyt
discuss
subcategori
licens
vaccin
adjuv
includ
miner
salt
alum
aluminum
hydroxid
etc
oilinwat
emuls
liposom
virosom
combin
adjuv
hand
mani
adjuv
combin
adjuv
formul
explor
develop
includ
mani
clinic
test
vaxjo
webbas
databas
tool
vaccin
adjuv
informat
http
wwwviolinetorg
vaxjoadjuv
list
differ
vaccin
adjuv
compound
huvax
databas
anoth
vaccin
informat
tool
within
violonet
suit
list
human
vaccin
vaccin
candid
contain
adjuv
clinicaltri
gov
registri
databas
list
clinic
trial
global
involv
vaccin
adjuv
number
propos
indic
vaccin
adjuv
continu
expand
increas
knowledg
inform
enabl
ration
justif
new
combin
product
test
new
potenti
ligand
receptor
pathway
remaind
review
focuss
polyion
class
adjuv
aluminum
salt
gel
repres
vast
major
miner
salt
compound
use
vaccin
adjuv
calcium
phosphat
nonaluminum
miner
salt
adjuv
use
human
vaccin
though
sever
miner
hydroxid
also
test
systemat
model
nanomateri
measur
immun
effect
vitro
anim
model
describ
aluminum
salt
long
histori
use
comprehens
safeti
record
adjuv
incorpor
human
vaccin
begin
potassium
alum
diphtheria
tetanu
vaccin
aluminum
salt
adjuv
use
today
human
vaccin
gel
compris
oxid
phosphat
sulfat
salt
aluminum
past
particularli
discoveri
subsequ
howev
also
activ
cell
express
respond
tlr
tlrindepend
adjuv
red
act
directli
either
dc
accessori
cell
aluminum
salt
plg
msu
quila
activ
inflammasom
aluminum
salt
act
monocyt
macrophag
granulocyt
induc
cytokin
gener
local
immunostimulatori
environ
eventu
lead
dc
activ
addit
also
promot
monocyt
differenti
dc
also
activ
muscl
cell
inject
site
suggest
aluminum
salt
caus
local
necrosi
stromal
cell
lead
releas
uric
acid
endogen
danger
signal
activ
inflammasom
mast
cell
activ
also
act
adjuv
dcdepend
mechan
inkt
activ
agalc
present
lead
dc
activ
beta
glu
can
activ
dc
iscomatrix
directli
promot
crosspresent
dc
far
role
trl
shown
adjuv
action
polyelectrolyt
reproduc
de
greg
gorio
et
al
slight
updat
permiss
author
publish
elsevi
current
opinion
immunolog
decad
aluminum
oxid
sulfat
phosphat
salt
togeth
antigen
creat
toxoid
prepar
preform
gel
commonli
use
conveni
arguabl
control
product
qualiti
proprietari
formul
today
may
still
employ
situ
aluminum
salt
precipit
atom
macromolecular
structur
biolog
activ
aluminum
salt
studi
intens
stanley
hem
laboratori
seen
renasc
interest
area
nano
mesotechnolog
materi
scienc
rapid
advanc
immunolog
support
system
biolog
bioinformat
new
capabl
cell
biolog
microscopi
recombin
mous
genet
label
cumul
experi
establish
aluminum
salt
adjuv
enhanc
vaccin
induc
high
titer
igg
rel
long
last
immun
eas
formul
long
record
gener
safeti
elicit
strong
immun
polar
effect
creat
protect
immun
extracellular
pathogen
howev
aluminumbas
adjuv
also
induc
ige
antibodi
stimul
littl
cellmedi
cytotox
tcell
respons
inject
via
subcutan
intraderm
rout
administ
repeatedli
use
also
associ
occurr
granuloma
effect
use
aluminum
salt
adjuv
adapt
simpl
effect
specif
exampl
alter
rout
inject
anthrax
vaccin
histor
inject
subcutan
clearli
associ
record
advers
event
advis
rout
administr
chang
subcutan
intramuscular
rout
us
uk
licens
anthrax
adsorb
vaccin
biothrax
emerg
biosolut
inc
rockvil
md
usa
avp
public
health
england
london
uk
gener
combin
adjuv
formul
develop
impart
addit
cell
mediat
immun
product
combin
aluminum
hydroxyphosph
adjuv
creat
immun
use
europ
decad
recent
receiv
us
licens
use
vaccin
squalen
oil
emuls
contain
mpl
adsorb
aluminum
hydroxid
salt
beyond
combin
aluminum
salt
compound
investig
counter
ion
formul
structur
defin
nanomateri
shown
new
capabl
common
miner
salt
adjuv
use
licens
human
vaccin
describ
next
alum
defin
heterogen
class
hydrat
aluminum
doubl
salt
compos
aluminum
sulfat
plu
cation
typic
potassium
sodium
ammonium
today
alum
use
vaccin
formul
commonli
refer
potassium
salt
aluminum
sulfat
howev
salt
tripli
charg
metal
cation
may
replac
mix
aluminum
sulfat
includ
iron
magnesium
cobalt
present
depend
ident
puriti
sourc
materi
potassium
aluminum
sulfat
form
situ
mix
compon
salt
precipit
k
antigen
includ
dehydra
te
process
prepar
unfortun
term
alum
al
oh
frequent
interchang
aluminum
hydroxid
aluminum
salt
gener
lenient
use
either
alum
al
oh
avoid
propag
confus
notabl
inaccur
use
term
alum
confound
effort
compar
vaccin
adjuv
safeti
efficaci
differ
vaccin
formul
precaut
becom
import
aluminum
salt
use
benchmark
test
develop
new
adjuv
includ
aluminum
salt
gel
specif
size
surfac
chemistri
aluminum
hydroxid
gel
use
vaccin
chemic
defin
aluminum
oxyhydroxid
alo
oh
alhydrogel
brenntag
biosector
frederikssund
denmark
gmp
exampl
adjuv
subclass
aluminum
hydroxid
gel
describ
poorli
crystallin
amorph
pseudoboehmit
miner
structur
compris
mixtur
micronand
nanos
particl
form
aggreg
primari
crystal
nm
length
aluminum
oxyhydroxid
high
surfac
area
g
outer
layer
bind
antigen
bind
driven
princip
electrostat
forc
though
interact
occur
includ
hydrogenbond
hydrophob
bond
point
zero
charg
pzc
creat
posit
charg
surfac
neutral
ph
antigen
bind
princip
via
neg
charg
howev
pzc
bind
antigen
alter
substanti
effect
potenc
stabil
formul
specif
concentr
phosphat
counter
ion
summar
abil
simpli
alter
antigen
bind
affin
stabil
potenc
via
ligand
exchang
surfac
hydroxyl
phosphat
without
alter
antigen
provid
inexhttp
wwwecevrorg
http
dx
pensiv
rapid
rout
improv
capabl
adjuv
protein
antigen
aluminum
salt
gel
proteinaluminum
bond
tighten
prolong
storag
though
effect
also
partial
mitig
formul
mm
phosphat
aluminum
phosphat
use
vaccin
gel
made
aluminum
hydroxyphosph
al
oh
x
adjupho
brenntag
gmp
exampl
adjuv
subclass
aluminum
hydroxyphosph
amorph
miner
structur
planar
particl
mm
averag
diamet
specif
ratio
surfac
phosphat
hydroxyl
depend
manufactur
condit
pzc
rang
surfac
charg
posit
neutral
ph
contrast
unmodifi
aluminum
oxyhydroxid
aluminum
hydroxyphosph
dissolv
readili
aluminum
oxyhydroxid
follow
inject
releas
three
time
much
radiolabel
aluminum
month
measur
rabbit
commerci
calcium
phosphat
use
vaccin
nonstoichiometr
hydroxyapatit
although
name
impli
formula
studi
identifi
structur
x
oh
x
vari
therefor
aluminum
salt
equival
surfac
chemistri
particul
size
consid
interchang
adjuv
materi
direct
test
refer
comparison
adjuv
studi
establish
involv
inflam
masom
adjuv
activ
aluminum
salt
role
may
essenti
evid
role
signal
pathway
importantli
report
aluminum
salt
adjuv
interact
directli
dc
bind
plasma
membran
lipid
substanti
forc
surfac
bind
induc
lipid
sort
involv
aggreg
immunoreceptor
tyrosinebas
activ
motif
signalingcontain
receptor
cascad
phosphoinositid
kinasemedi
respons
result
high
affin
stabl
bind
cell
absenc
adjuv
interact
similar
damp
cascad
caus
monosodium
urat
crystal
origin
candid
model
aluminum
mode
action
help
explain
conflict
result
urat
crystal
aluminum
salt
adjuv
evid
support
model
aluminum
adjuv
intern
enter
cell
instead
deliv
admix
ed
antigen
passag
across
membran
recent
studi
aluminum
model
particul
materi
reveal
reproduc
effect
materi
size
surfac
chemistri
cell
respons
use
aluminum
salt
metal
oxid
materi
system
immunolog
investig
immun
signal
vitro
vivo
studi
also
explain
part
immun
polar
particl
size
shown
import
paramet
vaccin
adjuv
nanomet
size
rang
nm
particularli
activ
may
due
due
cell
present
effect
cellular
uptak
membran
perturb
larger
particl
exert
differ
effect
innat
immun
signal
activ
inflammasom
crystallin
particl
exceed
nm
threshold
fulli
engulf
macrophag
vitro
creat
frustrat
phagocytosi
effect
activ
proinflammatori
respons
whose
chronic
stimul
lung
may
lead
medic
complic
includ
fibrosi
cancer
studi
use
silver
nanowir
confirm
effect
vivo
impli
chronic
exposur
may
contribut
toxic
fibrou
materi
asbesto
relev
adjuv
immun
signal
particul
adjuv
includ
aluminum
salt
find
gradat
effect
vivo
full
phagocytosi
materi
nm
give
proinflammatori
signal
yet
complet
phagocytosi
proinflammatori
signal
materi
size
mm
thu
specif
size
rel
inert
crystallin
materi
signal
innat
immun
without
antigen
effect
vari
proinflammatori
respons
function
adjuvant
frustrat
phagocytosi
find
relev
aluminum
salt
gel
partli
crystallin
popul
rang
size
thu
becom
evid
physic
dimens
may
use
attribut
measur
control
aluminumbas
adjuv
materi
studi
also
demonstr
strong
effect
surfac
chemistri
aluminum
salt
adjuv
immun
potenti
activ
particular
surfac
densiti
hydroxyl
group
correl
posit
proinflammatori
respons
agreement
prior
find
regard
effect
phosphat
counter
ion
antigen
bind
biolog
function
commerci
avail
aluminum
oxyhydroxid
alhydrogel
watkinson
et
al
use
recombin
anthrax
protect
antigen
rpa
model
antigen
investig
aluminum
structurefunct
effect
depend
adjuv
track
record
aluminum
oxyhydroxid
use
histori
differ
potenc
stabil
variou
produc
systemat
investig
phosphat
bind
thermodynam
kinet
alhydrogelrpa
interact
phosphat
mm
shown
convert
thermodynam
control
bind
antigen
endotherm
exotherm
restor
thermost
bound
antigen
resembl
solubl
form
due
alter
bind
creat
via
lignd
exchang
phosphat
surfac
hydroxyl
optimum
effect
mm
concentr
mm
phosphat
alhydrogel
formul
increas
potenc
compar
mm
phosphat
concentr
convent
phosphat
buffer
salin
formul
rpa
alhydrogel
stabil
trend
analysi
use
pool
mous
potenc
data
three
batch
mm
phosphat
formul
vaccin
compar
freshli
formul
standard
phosphat
formul
vaccin
show
estim
month
shelf
life
base
confid
interv
cross
rel
potenc
lower
limit
standard
deviat
thu
substanti
improv
potenc
stabil
engin
convent
alhydrogel
vaccin
simpli
use
defin
small
chang
phosphat
counter
ion
concentr
altern
improv
efficaci
afford
phosphatebas
bind
aluminum
salt
adjuv
may
also
achiev
reengin
antigen
coval
phosphon
linker
studi
establish
surfac
chemistri
particl
size
structur
import
attribut
aluminum
gel
measur
control
commonlyknown
exampl
autoclav
treatment
chang
physicochem
structur
aluminum
gel
affect
adjuv
properti
sinc
current
commerci
aluminum
base
gel
heterogen
size
well
chemic
composit
degre
specif
effect
adjuv
expect
priori
replic
across
chemic
class
manufactur
lot
requir
experiment
confirm
thu
content
size
matter
leverag
capabl
familiar
safeti
aluminum
salt
gel
mix
adjuv
extend
vaccin
capabl
control
therein
aid
compar
studi
improv
oldest
frequent
use
class
adjuv
gener
known
least
decad
polyelectrolytesion
macromolecul
either
synthet
natur
originserv
immunostimul
introduc
mixtur
typic
antigen
therebi
enhanc
immun
respons
sever
fold
moreov
effect
increas
order
magnitud
antigen
chemic
bound
synthet
polyelectrolyt
suggest
membran
activ
immunostimul
inher
polyelectrolyt
differ
chemic
structur
repeat
unit
class
depend
critic
molecular
size
selfassembl
characterist
system
although
exampl
licens
product
clinic
use
materi
famili
polym
gener
review
less
frequent
immunoadjuv
literatur
may
partli
due
challeng
relat
isol
purif
character
natur
synthet
polyelectrolyt
addit
abil
selfassembl
aqueou
solut
certain
condit
often
lead
poor
reproduc
conflict
result
difficulti
interpret
nevertheless
synthet
purif
approach
class
polym
greatli
improv
bodi
literatur
relat
compound
rapidli
grow
natur
synthet
polyelectrolyt
possess
number
common
featur
paramet
affect
biolog
function
solut
import
paramet
length
conform
polym
chain
type
repeat
unit
flexibl
backbon
ionic
densiti
tactic
regular
repeat
unit
solvent
interact
paramet
hydrodynam
behavior
thu
summar
report
relat
immunoadjuv
properti
polym
import
review
literatur
relat
natur
synthet
type
longchain
polyion
macromolecul
chitin
deriv
chitosan
linear
polysaccharid
increas
attent
biomateri
drug
deliveri
carrier
immunomodul
chitin
longchain
polym
nacetyldglucosamin
one
abund
polysaccharid
natur
life
scienc
applic
somewhat
limit
due
insolubl
water
contrast
chitosan
produc
partial
deacetyl
chitin
copolym
consist
randomli
distribut
ioniz
dglucosamin
deacetyl
unit
nacetyldglucosamin
acetyl
unit
fig
consequ
amend
watersolubl
hydrogel
http
wwwecevrorg
http
dx
nanoparticul
formul
moreov
cation
deriv
chitosan
provid
improv
watersolubl
also
wide
test
multipl
report
chitin
stimul
macrophag
produc
cytokin
confer
antitumor
activ
nonspecif
host
resist
bacteri
viral
infect
conceiv
chitin
could
potent
innat
immun
stimul
macrophag
innat
immun
cell
report
stimul
macrophag
interact
differ
cell
surfac
receptor
macrophag
mannos
receptor
ctype
lectin
receptor
leukotrien
receptor
must
emphas
isol
chitin
present
two
difficulti
relat
waterinsolubl
due
insolubl
chemic
structur
chitin
defin
physiolog
condit
may
involv
concurr
destruct
formul
alway
evalu
particul
mention
host
respons
vari
dramat
depend
size
possibl
natur
chitin
employ
well
method
prepar
time
rout
administr
contrari
chitin
chitosan
formul
prepar
hydrolysi
either
watersolubl
mix
polym
hydrogel
nanoparticul
therefor
amen
character
chitin
unless
polym
addit
modifi
watersolubl
chitosan
typic
limit
slightli
acid
acid
condit
unfortun
upon
review
literatur
alway
possibl
elucid
physic
even
chemic
form
chitosan
evalu
assess
activ
becom
complic
variou
rout
administr
use
chitosan
shown
mucoadhes
promot
prolong
retent
time
follow
mucos
vaccin
addit
act
permeat
enhanc
open
tight
junction
howev
number
studi
report
recent
focus
evalu
wellcharacter
origin
materi
necessarili
detail
formul
howev
one
well
defin
chitosan
test
parenter
immun
mice
use
model
antigen
shown
enhanc
antigen
specif
antibodi
titer
fivefold
antigenspecif
splenic
prolifer
sixfold
accord
author
strong
increas
antibodi
titer
togeth
robust
delayedtyp
hypersensit
respons
reveal
chitosan
induc
mix
humor
cellmedi
immun
respons
studi
chitosan
demonstr
equipot
ifa
superior
imject
alum
aluminum
hydroxid
aluminum
magnesium
hydroxid
mechanist
studi
reveal
viscou
chitosan
solut
creat
antigen
depot
inject
subcutan
also
induc
transient
cellular
expans
drain
lymph
node
also
shown
chitosan
synergist
enhanc
immunoadjuv
properti
granulocytemacrophag
colonystimul
factor
pleiotrop
proinflammatori
cytokin
initi
discov
growth
factor
capabl
gener
granulocyt
macrophag
coloni
bone
marrow
precursor
cell
separ
studi
evalu
three
differ
welldefin
type
chitosan
parenter
administr
model
antigen
ovalbumin
mice
show
adjuv
activ
case
exceed
alum
alusgel
alu
minum
hydroxid
sensit
phosphat
howev
adjuv
activ
vari
significantli
depend
formul
author
conclud
probabl
result
interplay
molecular
weight
particl
size
prepar
techniqu
solubl
viscos
well
degre
deacetyl
wherea
impur
found
play
minor
role
nevertheless
author
also
note
potenti
activ
prr
cell
innat
immun
system
report
chitin
deriv
potenti
explain
presenc
bacteri
fungal
contamin
endotoxin
sinc
materi
natur
origin
ionic
natur
complic
purif
effort
alreadi
note
observ
mirror
recent
publish
review
emphas
major
public
adjuv
activ
chitosan
date
molecular
weight
viscos
deacetyl
degre
puriti
level
especi
endotoxin
provid
chitosan
investig
final
formul
prepar
procedur
suffici
detail
due
evalu
adjuv
properti
challeng
especi
concern
elucid
mechan
action
exclus
potenti
interfer
due
impur
algin
acid
linear
copolym
contain
link
epim
g
residu
coval
link
togeth
differ
sequenc
block
fig
although
algin
wide
use
prepar
hydrogel
microspher
nanospher
encapsul
biolog
agent
also
report
adjuv
activ
solubl
salt
algin
acid
adjuv
effect
steril
sodium
algin
investig
subcutan
immun
bcg
vaccin
balb
c
mice
prolif
delayedtyp
hypersensit
respons
interferon
ifn
g
specif
antimycobacterium
total
igg
product
found
significantli
higher
mice
immun
adjuv
formul
addit
follow
system
infect
bcg
mice
vaccin
bcg
plu
algin
lower
mean
bacteri
count
compar
vaccin
bcg
alon
effect
sodium
algin
also
evalu
combin
microparticl
carrier
fabric
use
biodegrad
polymerpoli
lacticcoglycol
acid
plga
two
malaria
synthet
peptid
despit
fact
formul
practic
indistinguish
term
size
morpholog
addit
algin
improv
encapsul
effici
immun
respons
immun
studi
balbc
mice
intraderm
rout
demonstr
incorpor
algin
elicit
higher
humor
cellular
immun
respons
lead
balanc
respons
furthermor
administr
microparticl
contain
rgdmodifi
algin
show
evid
cell
target
enhanc
immunogen
microparticl
particular
regard
cellular
respons
ifnc
secret
lymphoprolifer
polyoxidoniuma
watersolubl
cation
polym
polyelectrolyt
specif
design
immunomodul
use
vaccin
ternari
copolym
ncarboxymethylen
bromid
molecular
weight
kda
fig
deriv
poli
synthes
partial
oxid
parent
polym
hydrogen
peroxid
introduc
noxid
group
follow
quatern
nonoxid
aminogroup
bromoacet
acid
introduct
noxid
group
critic
import
optim
composit
select
order
minim
toxic
typic
inher
polyamin
maintain
appropri
level
immunostimul
addit
noxid
unit
backbon
capabl
degrad
elev
temperatur
rearrang
oxim
amin
aldehyd
group
result
copolym
chain
cleav
shorter
fragment
releas
bodi
analysi
immunomodul
effect
induc
polyoxidonium
prove
stimul
activ
proinflammatori
cytokin
product
vitro
tumor
necrosi
factor
tnf
dosedepend
increas
intracellular
kill
blood
phagocyt
also
observ
polym
anoth
studi
establish
polyoxidonium
could
affect
bactericid
activ
leukocyt
mani
chronic
infecti
inflammatori
diseas
character
sluggish
recurr
cours
resist
adequ
therapi
requir
addit
immunostimul
establish
onehour
incub
human
peripher
blood
leukocyt
polyoxidonium
fig
schemat
chemic
structur
algin
acid
creas
abil
leukocyt
kill
ingest
staphylococcu
aureu
dosedepend
manner
increas
observ
leukocyt
obtain
healthi
person
patient
chronic
granulomat
diseas
polyoxidonium
also
shown
antioxid
activ
dose
rang
polyoxidonium
display
abil
enhanc
immun
respons
live
brucellosi
vaccin
brucella
abortu
strain
penicillin
sensit
guinea
pig
model
one
first
clinic
applic
polyoxidonium
commerci
influenza
vaccin
polyoxidonium
coval
conjug
antigen
compon
vaccinehemagglutinin
neuraminidas
reportedli
million
recipi
vaccin
extens
data
indic
efficaci
safeti
charact
prepar
obtain
clinic
studi
polyoxidonium
also
evalu
trival
live
attenu
measl
mump
rubella
vaccin
although
find
indic
healthi
children
need
fortif
immun
respons
vaccin
produc
high
level
specif
antibodi
children
previou
exposur
harm
factor
affect
normal
cell
content
viral
diseas
may
benefit
use
polyoxidonium
howev
author
also
note
detect
increas
level
skew
domin
immun
respons
type
could
appreci
posit
effect
polyoxidonium
environ
polyphosphazen
immunoadjuv
welldefin
macromolecul
design
around
biodegrad
phosphorusnitrogen
backbon
organ
side
group
contain
anion
moieti
macromolecul
uniqu
posit
among
class
synthet
natur
polyelectrolyt
due
number
structur
chemic
featur
among
hydrolyt
degrad
benign
degrad
product
control
via
select
appropri
side
group
flexibl
backbon
high
ionic
densiti
critic
selfassembl
biolog
target
tremend
divers
synthet
versatil
class
allow
creation
unpreced
macromolecular
structur
well
establish
synthet
rout
reproduc
high
level
puriti
eas
character
qualiti
control
adequ
stabil
mix
fix
aqueou
formul
approach
involv
coval
conjug
antigen
render
polym
attract
commerci
develop
poli
di
carboxylatophenoxi
phosphazen
pcpp
fig
far
investig
repres
class
success
advanc
develop
state
potent
immunoadjuv
effect
pcpp
welldocu
administ
varieti
bacteri
viral
antigen
dozen
anim
model
track
record
human
clinic
trial
includ
signific
improv
seroconvers
seroprotect
rate
season
influenza
vaccin
fourfold
rise
neutral
antibodi
respiratori
syncyti
viru
strain
greater
particip
vaccin
formul
contain
pcpp
report
safe
immunogen
immunoadjuv
effect
polyphosphazen
character
modul
onset
magnitud
qualiti
durat
immun
respons
report
polyphosphazen
adjuv
induc
signific
increas
antibodi
respons
earli
week
immun
number
antigen
includ
influenza
hepat
b
sustain
level
antibodi
titer
length
experi
week
observ
influenza
antigen
hepat
b
surfac
antigen
hbsag
anoth
import
featur
pcppantigen
sparingpcpp
adjuv
influenza
formul
inject
mice
potent
nonadjuv
counterpart
contain
time
higher
dose
antigen
import
featur
also
demonstr
lethal
challeng
studi
influenza
vaccin
ferret
highli
relev
preclin
model
experi
pcpp
formul
vaccin
afford
protect
mortal
wherea
nonadjuv
formul
protect
dose
least
higher
benchmark
polyphosphazen
adjuv
vaccin
contain
alum
aluminum
phosphat
suggest
either
greatli
superior
respons
polyphosphazen
anim
studi
least
equal
perform
human
pcpp
also
prove
work
well
gentl
antigen
viruslik
particl
vlp
singl
intramuscular
dose
pcpp
formul
rotaviru
vlp
induc
rotavirusspecif
serum
igg
iga
fecal
igg
titer
enhanc
adjuv
mechan
action
polyphosphazen
immunoadjuv
yet
fulli
understood
demonstr
molecular
level
paramet
interact
polyphosphazen
antigen
play
import
role
similarli
polyelectrolyt
adjuv
biolog
activ
pcpp
strongli
depend
associ
antigen
howev
contrari
convent
counterpart
pcpp
form
stabl
watersolubl
noncoval
complex
antigen
molecul
spontan
thu
requir
chemic
conjug
molecular
size
antigen
load
complex
shown
correl
activ
vivo
recent
studi
explor
effect
pcpp
multimer
formul
recombin
gaghiv
antigen
matur
activ
antigen
present
human
adult
newborn
dc
vitro
pcpp
treatment
induc
dc
activ
matur
assess
upregul
costimulatori
molecul
cytokin
product
effect
pcpp
found
robust
alum
adjupho
result
releas
mix
cytokin
respons
promot
cellular
potenti
humor
respons
formul
antigen
pcpp
also
induc
innat
immun
transcriptom
human
adult
newborn
dc
author
note
abil
pcpp
activ
neonat
monocyt
deriv
ed
dc
level
similar
adult
counterpart
particularli
noteworthi
suggest
adjuvant
platform
may
addit
applic
earli
life
immun
key
point
healthcar
contact
impair
immun
respons
note
mani
current
vaccin
formul
much
attent
also
focus
next
gener
polyphosphazen
adjuv
clearli
elucid
structur
composit
polyphosphazen
play
import
role
immunopotenti
effect
novel
molecul
differenti
significantli
pcpp
activ
mechan
action
although
two
dozen
new
gener
polyphosphazen
synthes
explor
immunoadjuv
properti
name
pcpp
copolym
contain
oxyethelyn
side
group
fig
poli
di
carboxylatoethylphenoxi
phosphazen
pcep
fig
found
depend
type
polyphosphazen
igg
isotyp
profil
immun
respons
vari
indic
potenti
differ
mechan
action
pcpp
primarili
enhanc
antibodi
respons
typic
associ
respons
wherea
sister
polym
shown
also
enhanc
associ
immun
respons
provid
protect
intracellular
pathogen
report
recent
pcep
induc
timedepend
chang
gene
express
mani
adjuv
core
respons
gene
includ
cytokin
chemokin
innat
immun
receptor
ifninduc
gene
adhes
molecul
antigenpresent
gene
upregul
gene
express
inflammasom
receptor
induc
product
proinflammatori
cytokin
site
inject
sinc
secret
cytokin
predominantli
result
activ
inflammasom
lead
process
secret
proinflammatori
cytokin
author
suggest
pcep
may
modul
antigenspecif
immun
respons
activ
earli
innat
immun
respons
promot
strong
immunostimulatori
environ
site
inject
intramuscular
inject
mice
pcep
induc
signific
recruit
neutrophil
macrophag
monocyt
dc
lymphocyt
site
inject
well
drain
lymph
node
result
confoc
analysi
reveal
intracytoplasm
lysosom
local
pcep
recruit
immun
cell
although
recent
public
especi
newer
gener
polyphosphazen
clearli
shed
light
mechan
action
note
paper
detail
synthesi
character
formul
studi
certainli
need
address
allow
exclus
impact
secondari
factor
molecular
size
polym
potenti
selfassembl
solut
even
effect
structur
irregular
polym
immunolog
effect
solubl
polyphosphazen
immunoadjuv
neutral
basic
aqueou
solut
provid
straightforward
formul
howev
conformationact
molecular
weightact
relationship
well
ionic
sensit
may
play
import
role
biolog
activ
therefor
formul
must
character
test
compat
specif
antigen
optim
accordingli
achiev
superior
result
importantli
due
watersolubl
welldefin
structur
polyphosphazen
provid
attract
basi
develop
combin
adjuv
fact
synergist
effect
pcpp
pcep
import
adjuv
cpg
well
establish
although
major
result
polyphosphazen
adjuv
report
watersolubl
formul
versatil
polym
allow
use
nanoparti
culat
deliveri
system
microneedl
intraderm
immun
fact
pcpp
copolym
easili
conform
hydrogel
nanoor
microparticl
aqueou
solut
use
ionic
complex
process
benign
agent
calcium
chlorid
spermin
contrari
nanoparticl
compris
hydrophob
biodegrad
nanoparticl
like
plga
aqueou
technolog
highli
protein
compat
nt
requir
use
organ
solvent
elev
temperatur
complex
manufactur
equip
although
result
system
well
character
allow
control
size
surfac
characterist
provid
slow
releas
antigen
immunoadjuv
immunolog
behavior
antigen
deliveri
capabl
yet
studi
systemat
anoth
attract
featur
polyphosphazen
adjuv
compat
variou
intraderm
immun
techniqu
concept
fabric
microneedl
use
pcpp
construct
materi
stem
macromolecular
natur
adjuv
determin
requir
set
mechan
properti
strength
film
form
characterist
adhes
featur
combin
excel
watersolubl
make
polyphosphazen
adjuv
attract
platform
vaccin
transderm
patch
technolog
polyphosphazen
enabl
straightforward
product
coat
dissolv
microneedl
excel
skin
penetr
capabl
fast
formul
dissolut
profil
microneedl
appli
skin
immun
microneedl
contain
recombin
hbsag
pcpp
pig
result
increas
antibodi
titer
least
higher
intramuscular
group
similar
formul
inject
intramuscularli
solut
three
order
magnitud
higher
nonadjuv
group
studi
pcpp
microneedl
also
show
substanti
potenti
antigen
dose
spare
overal
welldefin
natur
synthet
class
adjuv
biodegrad
natur
abil
finetun
structur
achiev
optim
immun
respons
modul
qualiti
compat
adjuv
versatil
formul
make
class
adjuv
especi
attract
challeng
applic
continu
advanc
harmon
intern
regul
aid
develop
adjuv
vaccin
adjuv
licens
whole
vaccin
product
strictli
specif
adjuvantantigen
formul
vaccin
separ
adjuv
entiti
test
document
adjuv
consid
relat
whole
vaccin
formul
review
safeti
toler
toxic
potenc
efficaci
effort
toward
harmon
biolog
drug
product
regul
unit
state
europ
japan
progress
sinc
present
mutual
recognit
licens
lot
releas
vaccin
recent
biennial
survey
report
europ
manufactur
dose
made
world
market
vaccin
product
therefor
full
align
regulatori
rule
guidelin
aid
develop
review
licens
adjuv
compon
vaccin
enter
global
commerc
standard
scientif
nomenclatur
laboratori
practic
aid
ongo
develop
applic
vaccin
adjuv
particularli
new
combin
adjuv
devis
compar
import
research
develop
effort
well
manufactur
preclin
test
note
wider
use
standard
help
anim
vitro
model
special
concern
due
variat
cell
line
laboratori
strain
effort
complet
possibl
describ
commun
regard
germ
line
immun
system
receptor
allel
tlr
cd
lectinbind
etc
allel
impact
use
surrog
diseas
indic
directli
test
peopl
anthrax
vaccin
biodefens
mention
character
compound
structur
use
relev
name
critic
import
compar
effect
safeti
vaccin
adjuv
gener
use
term
alum
al
caus
confus
confound
sciencebas
commun
safeti
aluminum
gel
heterogen
composit
higher
order
structur
polym
may
copolym
homopolym
residu
group
longer
serv
common
interest
scienc
technolog
adjuv
provid
common
name
best
effort
accur
name
experiment
character
composit
structur
need
advanc
polym
field
vaccin
deliveri
immunopotenti
larg
explain
physicochem
properti
allow
use
materi
prepar
nanoparticl
encapsul
antigen
polym
copolym
lactic
glycol
acid
one
common
choic
applic
ionic
macromolecul
synthet
natur
provid
import
altern
approach
afford
similar
physic
properti
stem
macromolecular
natur
offer
protein
friendli
aqueou
environ
antigen
encapsul
addit
integr
physic
characterist
vaccin
carrier
power
immunopotenti
properti
clear
system
begin
attract
increas
attent
academ
industri
research
much
progress
made
term
studi
biolog
relev
properti
mechan
action
howev
futur
develop
imped
lack
standard
approach
basic
character
system
especi
relev
macromolecul
natur
sourc
although
excel
immunolog
research
conduct
chitin
chitosan
absolut
major
paper
lack
fundament
descript
materi
use
studi
especi
concern
method
isol
chitin
well
puriti
level
vari
dramat
insolubl
condit
use
pose
sever
restrict
analyt
approach
chitosan
although
provid
watersolubl
mixtur
copolym
vari
composit
random
distribut
repeat
unit
molecular
size
proper
analysi
polym
composit
molecular
character
use
common
analyt
techniqu
clearli
absolut
necess
establish
proper
structur
activ
relationship
futur
develop
field
situat
becom
even
challeng
lack
appropri
analysi
complic
insuffici
character
nanoparticl
regard
synthet
polyelectrolyt
polyphosphazen
polyoxidonium
better
posit
due
welldefin
product
process
simplic
molecular
structur
nevertheless
emphas
even
molecul
contain
structur
irregular
contamin
shown
affect
perform
vivo
clear
need
thorough
character
system
order
avoid
potenti
misinterpret
result
fortun
welldefin
structur
watersolubl
macromolecul
allow
applic
whole
array
power
analyt
method
current
employ
polym
scienc
nuclear
magnet
reson
size
exclus
chromatographi
field
flow
fraction
capillari
electrophoresi
dynam
static
light
scatter
among
techniqu
success
appli
avoid
undesir
ambigu
interpret
result
develop
import
class
immunopotenti
vaccin
deliveri
vehicl
build
reliabl
product
character
method
technolog
crossroad
immunolog
cell
biolog
bioinformat
nanotechnolog
materi
scienc
public
health
sever
area
scientif
knowledg
practic
review
updat
aspect
adjuv
adjuvant
trace
current
state
knowledg
back
origin
adjuv
use
scienc
focus
particl
colloid
polyion
compositionaluminum
salt
gel
polyelectrolyt
polymerswhich
histor
remain
import
vaccin
product
develop
evid
show
nanoparticul
structur
surfac
chemistri
aluminum
salt
compound
critic
determin
adjuv
activ
therefor
measur
control
attribut
improv
compar
capabl
qualiti
product
develop
oldest
vaccin
adjuv
definit
control
surfac
chemistri
molecular
structur
also
import
polyelectrolyt
polym
adjuv
recent
inform
improv
understand
molecular
structur
interact
immun
cell
mechan
action
continu
subject
intens
studi
quest
expand
applic
util
vaccin
technolog
adjuv
includ
polyion
materi
like
gain
greater
import
develop
newer
vaccin
greater
capabl
safeti
